Prespecified analysis of EPIC-CAD (1,040 patients with AF and stable CAD): edoxaban monotherapy vs edoxaban plus an antiplatelet cut 12-month NACE with low (12.1% vs 21.7%; HR 0.52) and high creatinine clearance (5.2% vs 14.5%; HR 0.40); no interaction.
Secondary analysisn = 1,040
Lee et al. Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial